Search for: "In Re: Pharmastem Therapeutics, Inc."
Results 1 - 14
of 14
Sorted by Relevance
|
Sort by Date
22 Jul 2010, 11:59 am
See PharmaStem Therapeutics, Inc. v. [read post]
3 Mar 2008, 9:27 pm
Pharmastem Therapeutics, Inc. v. [read post]
12 Apr 2014, 6:39 am
See PharmaStem Therapeutics, Inc. v.ViaCell, Inc., 491 F.3d 1342, 1363-64 (Fed. [read post]
15 Aug 2007, 10:01 pm
In PharmaStem Therapeutics, Inc. v. [read post]
3 Sep 2015, 11:36 am
Cir.2012) (quoting PharmaStem Therapeutics, Inc. v. [read post]
14 Jul 2008, 9:17 am
Cir. 2001)); accord PharmaStem Therapeutics, Inc. v. [read post]
13 Mar 2011, 1:50 pm
Vast Res., Inc., 563 F.3d 1334, 1337 (Fed. [read post]
24 Sep 2010, 1:15 pm
PharmaStem Therapeutics, Inc. v. [read post]
2 Sep 2010, 10:51 am
Consideration of Evidence PharmaStem Therapeutics, Inc. v. [read post]
25 Mar 2011, 11:43 am
A reference is prior art for all that it discloses:A reference, however, is prior art for all that it discloses, and there is no requirement that a teaching in the prior art be scientifically tested, see PharmaStem Therapeutics, Inc. v. [read post]
22 Jul 2010, 8:15 pm
See PharmaStem Therapeutics, Inc. v. [read post]
25 Mar 2011, 8:29 pm
A reference, however, is prior art for all that it discloses, and there is no requirement that a teaching in the prior art be scientifically tested, see PharmaStem Therapeutics, Inc. v. [read post]
15 Feb 2008, 9:00 am
: (Spicy IP),USD 20 billion going off-patent: (Patent Circle),Canadian Prices Review Board asserts jurisdiction over products sold in US, but imported into Canada under Special Access Program: (Gowlings),Canadian Court of Appeal affirms decision allowing patent-owner to be joined to proceedings: Cobalt v Pfizer and Pharmascience v Pfizer: (Gowlings),PharmaStem appeals stem cell patent: asks for greater deference to patent examiners:… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
